SYDNEY, Jan. 23, 2015 /PRNewswire/ -- Novogen (ASX: NRT; NASDAQ: NVGN), an Australian-US drug discovery company focused on the development of novel therapeutics in the fields of oncology, degenerative disease and regenerative medicine, announced today that Graham Kelly, Ph.D., CEO and Executive Chairman, will present at the Biotech and Money London investor conference held during the 3rd-4th of February 2015.
About Biotech and Money London
Biotech and Money London 2015 is a two-day congress providing the education, strategies and solutions executives need to enable more effective funding, investment, business planning and partnering within your business.
It's where life science meets money, investors uncover innovation and pharma seek partners.
For more information visit the website: http://biotechandmoney.com/london
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.
The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.
The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate ('Anisina').
Further information is available on our websites www.novogen.com
For more information please contact:
SOURCE Novogen Ltd